Jyseleca

Filgotinib, the active ingredient in Jyseleca, is a Janus kinase (JAK) inhibitor presented as an oral tablet for oral use. It treats rheumatoid arthritis and ulcerative colitis in adult patients.

GNH USA supplies Jyseleca as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Filgotinib is a selective JAK1 inhibitor used in inflammatory autoimmune diseases.

Rheumatoid arthritis: reduces joint inflammation, pain, and slows structural damage progression. Ulcerative colitis: induces clinical remission and promotes mucosal healing in adults with moderate to severe disease.

Filgotinib may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea or vomiting - Headache - Upper respiratory tract infection - Elevated liver enzymes - Increased cholesterol levels - Diarrhoea

Serious or Rare Side Effects: - Serious infections (e.g., tuberculosis, opportunistic infections) - Venous thromboembolism - Herpes zoster reactivation - Malignancies (e.g., lymphoma, lung cancer) - Severe hepatic injury

Before initiating therapy, clinicians should evaluate patient risk factors and monitor safety parameters.

Monitor liver function: perform baseline and periodic hepatic enzyme tests. Screen for infections: assess for active tuberculosis and hepatitis before treatment. Assess cardiovascular risk: consider history of thrombosis or atherosclerotic disease. Avoid in severe hepatic impairment: dose adjustment may be required or contraindicated. Pregnancy and lactation: safety unknown; use only if potential benefit justifies risk. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Filgotinib can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase filgotinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce filgotinib exposure. - Live vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): potential for enhanced anticoagulant effect. - Other immunosuppressants (e.g., methotrexate, biologics): additive immunosuppression risk. - Statins (e.g., simvastatin): may raise risk of myopathy when combined.